News stories about CytRx (NASDAQ:CYTR) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CytRx earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.1801640941831 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Separately, ValuEngine lowered shares of CytRx from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st.
Shares of CytRx stock opened at $1.61 on Wednesday. CytRx has a fifty-two week low of $1.50 and a fifty-two week high of $6.00.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by BBNS and is the property of of BBNS. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/03/28/cytrx-cytr-earns-daily-news-sentiment-rating-of-0-11/1964606.html.
CytRx Company Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.